Energy · Education
Strategic collaboration will expand education, battery collection initiatives and resources to help the waste and recycling industry safely manage the growing volume of end-of-life batteries The Battery Network along with the National Waste & Recycling Association (NWRA) and the National Waste & Recycling Foundation (NWRF) today announced a strategic partnership to strengthen battery safety educatio
Aug 15 · 00:20·PR Newswire
Finance · SaaS
HONG KONG, August 14, 2026 - In recent years, the digital economy has deeply penetrated global consumer markets. The online fashion industry, with its unique advantages of lightweight operations, high iteration speed, and global reach, has entered a golden period of rapid growth, unlocking substantial development space and opportunities for related sectors. In this context, enterprises equipped with digital core capabilities, global expansion advantages, and distinctive supply chain systems are gradually securing a competitive edge in industry development.
As a leading enterprise in the global online fashion industry, SHEIN accurately captures the trends of digital consumption. Relying on its original business model, intelligent supply chain system, and global operational capabilities, it continues to break through industry bottlenecks, drives the transformation and upgrading of the global fast fashion sector, and sets a benchmark for Chinese enterprises expanding overseas.
Benchmarking Against Fashion Enterprises Inditex and H&M: Forging a Distinctive LATR Operational Model
Founded in 2012, SHEIN is a global online fashion and lifestyle enterprise. The Company has consistently pursued a global footprint, benchmarking itself against leading international fashion conglomerates including Inditex and H&M, setting it apart from conventional region-focused Chinese brands.
The Company now owns an array of globally renowned fashion brands, with its business footprint spanning roughly 160 markets worldwide. It has cultivated diversified revenue streams to effectively mitigate risks stemming from over reliance on a single market, forged a robust and sophisticated global commercial ecosystem, and secured a prominent position within the core global fast fashion sector.
The distinctive LATR operational model is the core moat that propels SHEIN to the forefront of the industry. In contrast to peers such as Inditex and H&M, whose models tend to converge and lack meaningful differentiation, SHEIN’s proprietary operational system has significantly optimized the operational value chain of the fashion industry, cultivating a distinctive and defensible competitive advantage.
In terms of business model innovation, SHEIN has achieved a disruptive breakthrough by pioneering its proprietary operational model, the Large-scale Automated Test Reorder (LATR) system. This model represents the optimal solution to the long-standing trilemma confronting the fashion apparel industry, and has fundamentally revolutionized the traditional operational logic governing apparel production, sales, and iteration.
Supported by the Company’s end-to-end smart supply chain and responsive global fulfillment infrastructure, the LATR system facilitates the optimal equilibrium across product assortment diversity, speed-to-market in design, and inventory control. Consequently, it addresses the persistent trilemma that has long beset the industry, and serves as a catalyst for the global fast-fashion sector’s transition from a conventional extensive-growth model to a refined, digitally-enabled, and sustainable development trajectory.
The impressive growth figures underscore SHEIN’s robust momentum. From 2023 to 2025, the Company’s active customers increased from 186 million to 273 million, representing a compound annual growth rate (CAGR) of 21.2%, significantly outpacing traditional international industry giants.
In terms of operational efficiency and value creation, SHEIN’s advantages are particularly distinctive. Its operational efficiency substantially surpasses that of its peers, with inventory turnover days of only 36 days, markedly better than the industry benchmarks of 71 days for Inditex, 114 days for Fast Retailing, and 164 days for Adidas.
Meanwhile, underpinned by a rigorous cost-control and highly pragmatic corporate culture, the Company has consistently pursued cost reduction and efficiency enhancement initiatives, continuously optimizing its cash flow. Furthermore, SHEIN demonstrates strong cash generation capabilities and has made a solemn commitment to maintain a dividend payout ratio of no less than 50% following its listing, thereby delivering stable returns to investors.
Sound Financial Fundamentals and Valuation on Par with Global Fashion Giants
Driven by its proven business model, continuously iterating technological capabilities, and global channel footprint, SHEIN has recorded sustained and solid growth in operating performance, alongside steadily improving profitability.
According to the Prospectus, SHEIN generated net revenue of US$41.8 billion in 2025, representing a CAGR of 14.2% from 2023 to 2025, with steady revenue expansion and sustained growth momentum. During the same period, the Company achieved a net profit of US$2.064 billion, reflecting excellent earnings quality and underscoring its exceptional operational resilience and growth vitality.
In the first quarter of 2026, the Company sustained its steady growth trajectory, generating net revenue of US$9.1 billion for the period, representing a year-over-year increase of 1.1%. Against the backdrop of global consumer market volatility and intensifying industry competition, it maintained positive growth, demonstrating solid commercialization and monetization capabilities as well as robust resilience to risks.
Against the industry benchmark of 25x price to earnings ratio (P/E ratio) for Inditex in FY2027 and 20x P/E ratio for H&M in FY2027, SHEIN, underpinned by its differentiated business model, strong growth momentum and leading operational efficiency, possesses the fundamental basis for a valuation that is comparable to, or even on par with, global fashion giants.
Current market analysts assign SHEIN a P/E valuation range of 20x to 30x, positioning it between H&M and Inditex. According to Reuters, the Company’s target valuation for this IPO is in the range of US$35 billion to US$40 billion, fully reflecting its solid operational fundamentals and long-term growth potential.
Innovation drives industrial upgrading. Deep cultivation fuels global development. With over a decade of deep engagement in the industry, SHEIN, leveraging its unique business model, solid supply chain capabilities and deep global brand equity, has completed a transformative leap from a rising Chinese cross-border player to a global fashion leader.
Following its successful listing on the Hong Kong capital market, SHEIN will leverage the international capital platform of the Hong Kong stock market to further deepen technological innovation, optimize its global footprint and reinforce its industry moats. With vast market headroom and abundant growth momentum, the Company’s future development potential is well worth investors’ high expectations.
Aug 14 · 07:41·ACN Newswire
Finance · AI
NEW YORK, Aug 13, 2026 - SunScout Holding Limited (NYSE American: SNSC) develops autonomous solar-powered robotic mowers and complementary solar energy solutions. The company has principal operations in New Zealand and the United States and is incorporated in the Cayman Islands.
SunScout commenced concurrent trading on NYSE American and NYSE Texas on August 12, 2026, becoming the first issuer with this combination of domicile and operational footprint to list on both exchanges. The offering was priced at $5.00 per Class A ordinary share, yielding gross proceeds of approximately $15.5 million. Upon closing, the company will have approximately 23.1 million Class A ordinary shares outstanding, implying a market capitalization of roughly $115.5 million based on the offer price.
NYSE Texas, launched by Intercontinental Exchange (ICE) in March 2025 and headquartered in Dallas, currently hosts listed companies with an aggregate market capitalization exceeding $3.9 trillion, positioning it as a significant U.S. capital‑markets hub. The dual listing is expected to enhance SunScout’s brand visibility across the United States, particularly in Texas, where the company is pursuing strategic expansion, while also broadening its investor base.
Three‑Pronged Clean‑Tech Portfolio; SunScout Products Emerges as Key Growth Driver
As detailed in its prospectus, SunScout designs, develops, manufactures, and commercializes autonomous solar‑powered robotic mowers alongside complementary solar‑energy solutions. Its operations are organized into three segments: SunScout Products (autonomous solar-powered robotic mowers and complementary products), solar power development solutions, and engineering products and services under the Brunton Engineering brand, which encompasses clean‑energy hardware and high‑precision manufacturing.
For the fiscal year ended June 30, 2025, the company reported total revenue of approximately $4.8 million, representing year‑over‑year growth of 93.6%. Solar power development solutions contributed approximately 40.9% of total revenue, while engineering products and services accounted for approximately 31.1%. Revenue from SunScout Products rose to approximately 28.0% of total revenue, up from approximately 18.5% in FY2024, demonstrating strong growth momentum.
The prospectus explicitly notes that while solar power development and engineering services currently generate the majority of top‑line revenue, the SunScout Products segment captures long‑term growth opportunities aligned with global market expansion and is positioned as a core growth engine, accelerating the company’s transition toward a higher‑value, product‑driven business model.
According to Mordor Intelligence, the global robotic lawn mower market is on a robust growth trajectory, valued at roughly $2.4 billion in 2025 and projected to reach $4.7 billion by 2030, at a compound annual growth rate (CAGR) of 14.4%. Robotic mowers still represent a small fraction of the broader lawn‑equipment market, leaving significant room for penetration.
Rising labor shortages and escalating lawn‑maintenance costs are fueling demand for automation. Concurrently, regulatory initiatives worldwide to phase out gasoline‑powered outdoor equipment are gaining momentum, accelerating industry electrification. Shifting consumer preferences toward intelligent, convenient solutions are fostering deeper integration of robotic mowers with smart‑home ecosystems and the Internet of Things (IoT), creating substantial headroom for automated electric mowing solutions.
Proprietary DSA Technology Enables True Off‑Grid Operation
SunScout’s core competitive advantage lies in its proprietary Deployable Solar Array (DSA) technology, which allows its robotic mowers to operate entirely on solar power, achieving genuine off‑grid performance without reliance on electrical outlets. Conventional gasoline‑powered mowers emit carbon emissions, and while existing electric mowers eliminate direct emissions, they remain dependent on fixed charging infrastructure, constraining operational range and flexibility.
The DSA mechanism enables solar panels to automatically deploy when stationary, tripling the surface area to maximize solar‑energy capture for onboard battery charging; panels retract during movement to preserve maneuverability. This design supports fully solar‑dependent, zero‑emission autonomous mowing, augmented by autonomous navigation and AI‑powered obstacle avoidance capabilities.
According to the company, few competing products can function completely independent of external power sources. This capability unlocks deployments at sites without power outlets or charging facilities—such as golf courses, public parks, and large‑scale green spaces—delivering meaningful advantages for continuous autonomous field operations. Over the longer term, DSA‑based hardware insulates operating costs from electricity‑price inflation and enables rollouts in regions with limited or unreliable grid infrastructure.
SunScout also emphasizes that its technology platform is highly adaptable and platform‑agnostic, opening potential applications beyond lawn mowing, including agricultural robotics, onboard solar‑charging systems for electric vehicles, autonomous patrol robots, and other mobile machinery.
Three‑Tier Product Lineup and Rapidly Expanding Global Distribution
SunScout’s autonomous solar‑powered robotic mower portfolio comprises three modular models: the residential‑grade SunScout Eco, light‑commercial SunScout Pro, and large‑institutional‑focused SunScout ProMax. The modular architecture supports incremental upgrades without extensive redesign, facilitating efficient global deployment across diverse terrain and climate conditions.
For example, the entry‑level SunScout Eco integrates high‑efficiency photovoltaic panels into the top housing, converting sunlight to supply all energy required for propulsion, cutting assemblies, and onboard electronics. The unit employs a multi‑sensor suite and AI‑enhanced dual‑camera visual navigation to map work zones, identify lawn boundaries and obstacles, and optimize mowing routes. For larger and more complex sites, RTK satellite navigation is available to deliver centimeter‑level positioning accuracy.
On commercial‑channel development, SunScout has established distribution partnerships with Wrissmer Werkstattsysteme GmbH (WWS) in Europe and MowBot Limited in Australia and New Zealand, and is in active discussions regarding potential distribution cooperation with major retailers, including Walmart.
Beyond robotic hardware, the company provides end‑to‑end solar power development solutions, including system design, installation, and full engineering, procurement, and construction (EPC) services for commercial, industrial, and institutional clients. Through its Brunton Engineering brand, it also offers engineering products and services leveraging nearly 30 years of precision‑fabrication and mechanical‑engineering expertise, and is an accredited supplier to the New Zealand Defence Force.
On the manufacturing front, assembly is currently conducted via SunScout Asia in Thailand. The company is advancing the establishment of an assembly and distribution center in Austin, Texas, through its U.S. subsidiary, which will build domestic production capacity and support long‑term North American expansion, aligning with U.S. policy emphasis on domestic robotics and technology supply chains. Recent actions by the U.S. Federal Communications Commission (FCC) restricting authorizations for certain foreign‑produced robotic products further underscore the growing importance of domestic manufacturing and supply‑chain resilience.
Net proceeds from the offering are expected to be used primarily for: (i) construction of the Austin manufacturing facility; (ii) sales and marketing activities; (iii) product research and development; (iv) inventory procurement; (v) repayment of one loan; (vi) consideration for the acquisition of Brightway Energy LLC; and (vii) general working capital purposes.
Against the backdrop of accelerating global clean‑energy transition and continued expansion of the robotic‑mower market, market participants will closely monitor whether SunScout can leverage its proprietary off‑grid solar‑robotics technology to differentiate itself amid intensifying industry competition.
Note: This translation has been calibrated against the company’s registration statement on Form F‑1 (File No. 333‑295248), as declared effective by the SEC on August 11, 2026. All financial data, segment descriptions, and legal status reflect the prospectus disclosures. Certain distributor names and retail discussions are retained as stated in the prospectus; for definitive terms, please refer to the final prospectus.
For more information, please contact:
Golden Fleece Cross-border Consulting Co., Limited
Email: heidiho@goldenfleece.hk
Aug 13 · 15:00·ACN Newswire
Finance · Sustainability
Highlights efforts on agriculture, emissions, packaging, and product shifts toward lower sugar, sodium and saturated fat PURCHASE, N.Y., Aug. 13, 2026 -- PepsiCo, Inc. (NASDAQ: PEP) on Thursday released its 2025 ESG Summary, web pages, and Leadership Message, updated ESG Topics A-Z
Aug 13 · 13:00·PepsiCo
Automotive · Industrial
+++ Research project highlights potential of high-quality material loops, particularly for steel, aluminium and copper +++ Car2Car rate increases from six to 51 percent under expanded processing and sorting conditions +++ Results provide important data basis for vehicle recycling +++
Aug 10 · 09:00·BMW Group
Healthcare · Biotech & pharma
Berlin, July 30, 2026 – Bayer today announced the submission of a New Drug Application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), seeking approval to extend the indication of finerenone in China to include adult patients with non-diabetic chronic kidney disease. The regulatory submission is supported by the positive results from the Phase III FIND-CKD study, which were presented at ERA Congress 2026 and simultaneously published in the New England Journal of Medicine.
Approximately 850 million people worldwide are living with chronic kidney disease (CKD) and more than half of them have non-diabetic CKD. Worldwide, more than 3.5 million people with kidney failure are treated with dialysis, which is associated with a 5-year survival rate of about 40% after treatment initiation. Non-diabetic CKD can have a range of etiologies, of which the most common include kidney disease linked to hypertension and glomerulonephritis (including IgAN and FSGS). Despite standard of care, patients with non-diabetic CKD remain at risk for kidney failure and cardiovascular events. Chronic kidney disease linked to hypertension is the second most common cause of kidney failure. In addition, patients with advanced non-diabetic CKD face a significantly increased risk for a fatal cardiovascular event, about 2.6 times higher than that of the general population without CKD, which increases further as kidney function declines.
“People living with non-diabetic chronic kidney disease (CKD) face a substantial risk for progressive kidney function decline and cardiovascular events. The FIND-CKD study adds robust evidence supporting the potential of finerenone to address this risk across a diverse range of non-diabetic CKD etiologies, including CKD due to hypertension and glomerular diseases,” said Dr. Christian Rommel, Global Head of Research and Development at Bayer’s Pharmaceuticals Division. “Building on the evidence generated across the finerenone clinical development program, the submission of these data marks an important step in our efforts to bring finerenone to more patients who may benefit from its cardio-kidney protective effects and reflects our commitment to advancing innovation for people living with heart and kidney diseases worldwide.”
Since 2021, finerenone has been marketed as Kerendia™ or, in selected countries, as Firialta™, and approved for the treatment of adult patients with CKD associated with type 2 diabetes (T2D) in more than 100 countries worldwide, including in China, Europe, Japan, and the U.S. Finerenone is also approved for the treatment of heart failure with left ventricular ejection fraction (LVEF) ≥ 40% in the U.S., the EU, in Japan, and in China, with additional applications under regulatory review.
About Kerendia™ / Firialta™ (finerenone)
Kerendia™ and Firialta™ are globally protected trademarks for finerenone. Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway that in five pivotal Phase III studies has demonstrated cardiovascular and/or kidney benefits across a broad range of patient populations, including patients with HF with left ventricular ejection fraction (LVEF) ≥40%, patients with CKD associated with type 2 diabetes, patients with CKD associated with type 1 diabetes, and patients with non-diabetic CKD. Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that has been shown to block harmful effects of MR overactivation. MR overactivation contributes to chronic kidney disease (CKD) progression and cardiovascular damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors.
The clinical study program with finerenone, FINEOVATE, currently comprises twelve Phase III studies with dedicated programs in CKD and HF respectively. The THUNDERBALL CKD program consists of the completed Phase III studies FIDELIO-DKD, FIGARO-DKD, FIND-CKD, and FINE-ONE, and the Phase II study CONFIDENCE; as well as the ongoing Phase III studies in pediatric patient populations FIONA, and FIONA-OLE. The MOONRAKER program includes the completed pivotal Phase III study FINEARTS-HF, the ongoing investigator-sponsored, collaborative studies REDEFINE-HF, CONFIRMATION-HF, and FINALITY-HF, as well as the ongoing Phase III studies in pediatric patient populations, FIORE and FIORELLO.
About FIND-CKD
FIND-CKD is the largest Phase III study to date focused on non-diabetic CKD. The study investigated finerenone in a broad patient population spanning different etiologies of non-diabetic CKD, adding to the positive data and breadth of evidence of finerenone in CKD associated with diabetes. FIND-CKD (FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease) investigated the efficacy and safety of finerenone compared to placebo in addition to standard of care in more than 1,500 patients with non-diabetic chronic kidney disease etiologies, including kidney disease linked to hypertension and glomerular diseases. Patients were randomized to receive either finerenone 10mg or 20mg or placebo on top of maximum tolerated labeled doses of a renin-angiotensin system (RAS)-blocking therapy such as an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB).
In the FIND-CKD study, finerenone showed a statistically significant and clinically meaningful improvement of kidney function compared with placebo: The mean annual decline in eGFR from baseline to 32 months (total slope) was −4.0 ml/minute/1.73 m2/year with placebo and −3.3 ml/minute/1.73 m2/year with finerenone, corresponding to a 0.7 ml/minute/1.73 m2/year slower decline with finerenone [95% CI, 0.3-1.1; p
Finerenone was well-tolerated in the FIND-CKD study, which is consistent with the well-established safety profile of finerenone.
About Chronic Kidney Disease
Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. Chronic Kidney Disease (CKD) represents a major global health challenge, affecting 850 million people worldwide – in fact, as the ninth leading cause of death, it results in 1.5 million fatalities each year, translating to one death every 20 seconds. In the U.S., 1 in 3 adults is at risk for the disease. At advanced stages of CKD, patients may need dialysis or a kidney transplant to stay alive. Healthy kidneys act as the body’s filter, removing waste products from the blood. They also control how much water and electrolytes are in the body, regulating blood pressure. As kidney function goes down, patients may experience a range of symptoms including leg swelling, tiredness in the day, nausea, muscle cramps, joint pain and confusion, trouble focusing, memory problems. Major underlying causes of CKD include diabetes, hypertension, and glomerular diseases such as immunoglobulin A nephropathy, focal segmental glomerulosclerosis and membranous nephropathy.
About Bayer’s Commitment in Cardiovascular and Kidney Diseases
Bayer is a leader in the area of cardiology and is advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The strategy is to unlock the strong potential of the future cardiovascular market by transforming Bayer’s portfolio into precision cardiology, addressing the high disease burden, and driving long-term growth. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular and kidney diseases are treated.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.
Find more information at https://pharma.bayer.com
Follow us on Facebook: http://www.facebook.com/bayer
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.
Jul 30 · 06:30·Bayer
AI · Education
The Netherlands-based, family-owned maritime group is charting a course toward a more intelligent, sustainable future.
Jul 20 · 11:15·SAP
Education · Sustainability
Five-year global partnership removes marine litter across 10 countries through diving missions and coastal cleanup
New ‘From Sea to Shore’ program in Southern California combines underwater recovery of ghost nets with employee engagement and youth education
Abandoned fishing nets transformed into ECONYL® yarn to support circular economy solutions
Hyundai Hope initiative engages Southern California community in ocean conservation and environmental stewardship
Jul 16 · 15:00·Hyundai Motor Company
SaaS · Healthcare
Monheim, July 15, 2026 – Bayer enters an exclusive licensing agreement with RAGT, a leading company in the European wheat seed market, advancing its plans to sell hybrid wheat seeds in Europe and North America simultaneously by the early 2030s. Hybrid wheat represents a large, untapped opportunity in the world’s most widely grown food crops and Bayer targets annual revenues of up to 1 billion euros after just over a decade after launch. The move is part of Bayer's growth ambitions beyond its current blockbuster launches by expanding its core portfolio to hybrid wheat as a key franchise.
The new agreement with RAGT materially strengthens Bayer’s position in Europe, as it involves the broad licensing of elite wheat germplasm tailored for European environments. This gives Bayer the ideal foundation to further advance and deploy its powerful breeding engine based on its longstanding hybrid wheat R&D efforts, to develop innovations that provide greater productivity and sustainability to farmers at a time when many face challenging weather and growing conditions.
“Wheat is one of the most important staple food crops in the world. But wheat production has stagnated and is coming under pressure from prolonged drought and heatwaves, such as the one we just experienced in Europe. At the same time, sturdier hybrid varieties of wheat are still not widely available,” said Peter Mueller, Cereals, Cotton, Canola/OSR & Biofuels Lead at Bayer’s Crop Science division. “Our deal with RAGT is about to change that. Combining RAGT’s top performing germplasm and know-how with our breeding capabilities will significantly boost and expand our pipeline of hybrid wheat varieties, allowing us to compete in a rapidly evolving market. With the North American program in full gear, we will deliver higher value to growers on both sides of the Atlantic.”
Sébastien Chatre, Head of R&D at RAGT added, “We’re very excited about the potential of this broad licensing agreement with Bayer, as it represents a significant step in RAGT’s commitment to innovation in wheat breeding. By sharing our expertise, we can accelerate the development of hybrid wheat solutions that will benefit the entire market and meet the evolving needs of farmers and the seed industry.”
For the European market, Bayer will focus its efforts on winter wheat. In North America, the company will introduce both spring and winter wheat, building on its successful WestBred wheat franchise. In both Europe and the U.S., the genetic material Bayer uses for breeding has the potential to fit in more than 80 percent of the wheat hectares, spanning across countries in Europe and across classes in the U.S. Bayer’s leading position in the crop protection space for wheat and the respective customer relations, combined with its access to elite germplasm for Europe and North America, precision breeding capabilities, seed production know-how, as well as digital and agronomic expertise will help the company build a competitive, holistic wheat system for farmers.
Hybrid wheat to deliver higher yields
Hybrid wheat seeds can increase wheat production without additional land or resource use, adding 10 percent compared to conventional open-pollinated wheat, right from the early stages of introduction of the new technology, with continuous additional yield gains going forward. Additional benefits for farmers include more reliability and robustness because key attributes of hybridization include an enhanced root system and faster growth to establish a strong crop against external factors, leading to potential better disease, weed and pest tolerance, and greater resilience to drought and heat.
With hybridization of wheat still largely untapped, investing in hybrid wheat presents a unique opportunity for growth and enhanced food security. As the world’s number one food crop, wheat covers over 220 million hectares globally and feeds around 30 percent of the population, making it an essential source of the world’s calories and a staple crop for fighting hunger. With climates in wheat-growing regions becoming hotter and drier, demand is continuing to increase further for resilient hybrid seeds that offer higher and more stable yields.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.
Jul 15 · 07:29·Bayer
AI · Energy
The report highlights measurable gains in climate action, circular economy, social impact, and governance, while reinforcing responsible innovation in the AI era and Lenovo’s continued commitment to ESG programs.
Jul 7 · 04:00·Lenovo
Finance · Sustainability
Accelerating performance across regenerative agriculture, restorative and protective practices, sustainable sourcing, and livelihoods ambitions worldwide PURCHASE, N.Y., July 1, 2026 -- PepsiCo (NASDAQ: PEP) today announced progress against its 2030 Positive Agriculture (pep+) goals,
Jul 1 · 12:30·PepsiCo
AI · Sustainability
2026 Sustainability Report details sustainability performance, achievements and future plans, enhancing transparency in line with global disclosure trends
Key annual achievements include RE100 fulfillment in Europe, North America and India and top safety ratings from the IIHS
Proactive risk management measures highlighted including the ‘AI Governance’ frameworks
A separate Summary Report available to improve accessibility, featuring key results and major sustainability topics
Jun 29 · 23:30·Hyundai Motor Company